Skip to main content
. 2020 Feb 3;11(8):2139–2149. doi: 10.7150/jca.38796

Table 1.

Clinical characteristic of patients with CRC in each set.

Clinical feature Test set(%) Validation set(%) Entire set (%)
Gender
Male 178(55.3) 148(50.7) 326(53.1)
Female 144(44.7) 144(49.3) 288(46.9)
Age
< = 68 166(51.6) 162(55.5) 328(53.4)
> 68 156(48.4) 130(44.5) 286(46.6)
T stage
T1+T2 61(19.0) 64(21.9) 125(20.4)
T3+T4 260(80.7) 228(78.1) 488(79.5)
unknown 1(0.3) 0(0.0) 1(0.1)
N stage
N0 194(60.2) 156(53.4) 350(57.0)
N1+N2 128(39.8) 136(46.6) 264(43.0)
M stage
M0 235(73.0) 222(76.0) 457(74.4)
M1 46(14.3) 41(14.0) 87(14.2)
unknown 41(12.7) 29(10.0) 70(11.4)
Stage
I+II 181(56.2) 150(51.4) 331(53.9)
III+IV 131(40.7) 136(46.6) 267(43.5)
unknown 10(3.1) 6(2.0) 16(2.6)
Neoplasm cancer status (with tumor/tumor free)
Tumor free 135(41.9) 120(41.1) 255(41.5)
With tumor 152(47.2) 137(46.9) 289(47.1)
unknown 35(10.9) 35(12.0) 70(11.4)
New tumor event after initial treatment(yes/no)
No 222(68.9) 187(64.0) 409(66.6)
Yes 52(16.1) 47(16.1) 99(16.1)
unknown 48(15.0) 58(19.9) 106(17.3)
Lymphatic invasion(yes/no)
No 171(53.1) 157(53.8) 328(53.4)
Yes 115(35.7) 112(38.4) 227(37.0)
unknown 36(11.2) 23(7.8) 59(9.6)
Residual tumor(yes/no)
No 230(71.4) 219(75.0) 449(73.2)
Yes 22(6.8) 20(6.8) 42(6.8)
unknown 70(31.8) 53(18.2) 123(20.0)